Shuichi Shirane

Tokyo, Japan

Last Updated: 09/26/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 52 publications

Modified short-course fludarabine-based conditioning regimen for salvage cord blood transplantation after graft failure.

Modified short-course fludarabine-based conditioning regimen for salvage cord blood transplantation after graft failure.

Journal: International journal of hematology

Published: February 03, 2026

Reversible Left Ventricular Dysfunction Related to Ropeginterferon Alfa-2b in Polycythemia Vera.

Reversible Left Ventricular Dysfunction Related to Ropeginterferon Alfa-2b in Polycythemia Vera.

Journal: International heart journal

Published: November 30, 2025

Risk Stratification Using Dynamic International Prognostic Scoring System and Splenomegaly in Myelofibrosis Treated with Pretransplant JAK Inhibitors.

Risk Stratification Using Dynamic International Prognostic Scoring System and Splenomegaly in Myelofibrosis Treated with Pretransplant JAK Inhibitors.

Journal: Transplantation and cellular therapy

Published: July 21, 2025

Risk Factors for and Impact of Pre-Engraftment Syndrome on Outcomes Following Single-Unit Cord Blood Transplantation in Adults.

Risk Factors for and Impact of Pre-Engraftment Syndrome on Outcomes Following Single-Unit Cord Blood Transplantation in Adults.

Journal: American journal of hematology

Published: July 06, 2025

Comparison of stem cell mobilization methods in multiple myeloma.

Comparison of stem cell mobilization methods in multiple myeloma.

Journal: Cytotherapy

Published: June 23, 2025

Ropeginterferon alfa-2b in hydroxyurea-intolerant or hydroxyurea-refractory essential thrombocythaemia (SURPASS ET): a multicentre, open-label, randomised, active-controlled, phase 3 study.

Ropeginterferon alfa-2b in hydroxyurea-intolerant or hydroxyurea-refractory essential thrombocythaemia (SURPASS ET): a multicentre, open-label, randomised, active-controlled, phase 3 study.

Journal: The Lancet. Haematology

Published: June 11, 2025

Correction: Long-term safety and efficacy of ropeginterferon alfa-2b in Japanese patients with polycythemia vera.

Correction: Long-term safety and efficacy of ropeginterferon alfa-2b in Japanese patients with polycythemia vera.

Journal: International journal of hematology

Published: May 16, 2025

Improved Transplant Outcomes With Alternative Donors in Myelofibrosis: A 20-Year Japanese Registry Analysis of Donor Sources and the Impact of Ruxolitinib.

Improved Transplant Outcomes With Alternative Donors in Myelofibrosis: A 20-Year Japanese Registry Analysis of Donor Sources and the Impact of Ruxolitinib.

Journal: American journal of hematology

Published: February 20, 2025

Ropeginterferon-α2b discontinuation after long-term exposure: four cases from a single institution.

Ropeginterferon-α2b discontinuation after long-term exposure: four cases from a single institution.

Journal: International journal of hematology

Published: January 29, 2025

A higher JAK2V617F allele burden may be a risk factor for hemorrhagic events in younger patients with polycythemia vera.

A higher JAK2V617F allele burden may be a risk factor for hemorrhagic events in younger patients with polycythemia vera.

Journal: Hematology (Amsterdam, Netherlands)

Published: November 15, 2024

Assessment and management of pregnancy in patients with myeloproliferative neoplasms: insights from a single-institution study of 29 neonates.

Assessment and management of pregnancy in patients with myeloproliferative neoplasms: insights from a single-institution study of 29 neonates.

Journal: International journal of hematology

Published: October 22, 2024

Budd-Chiari syndrome and JAK2 gene mutation

Budd-Chiari syndrome and JAK2 gene mutation

Journal: [Rinsho ketsueki] The Japanese journal of clinical hematology

Published: September 04, 2024

Showing 1-12 of 52

Last Updated: 09/26/2026